Amyotrophic lateral sclerosis (ALS), the most common adult onset motor neuron disease, is pathologically characterized by progressive loss of the upper and lower motor neurons. Mutations in the Cu/Zn superoxide dismutase gene (SOD1) account for about 20% of familial ALS cases and a small percentage of sporadic ALS (SALS) cases, and have revealed a validated genotype-phenotype correlation. Herein, we report a p.Gly13Arg mutation in SOD1 exon 1 in a patient with SALS who presented with a rapidly progressive course, predominantly affecting the lower motor neurons. A 48-year-old man presented with progressive weakness and muscle atrophy of the left upper and lower limbs, followed by muscle fasciculation and cramping. The clinical features of the patient were clearly suggestive of ALS, and implied a sporadic form with rapid progression, predominantly affecting the lower motor neurons. Sequencing of the SOD1 gene by PCR revealed a missense mutation of G to C (c.37G>C) in exon 1, and amino acid substitution of glycine by arginine (p.Gly13Arg). This is the first case identifying the p.Gly13Arg mutation of SOD1 in the Korean population, and clinical assessments of this patient revealed a different phenotype compared with other cases.

Key words: Amyotrophic lateral sclerosis, ALS, Cu/Zn superoxide dismutase 1, SOD1, Exon 1

INTRODUCTION

Amyotrophic lateral sclerosis (ALS), the most common adult onset motor neuron disease, is pathologically characterized by progressive loss of the upper and lower motor neurons in the brainstem motor nuclei and the anterior horn of the spinal cord [1, 2]. This pattern of neurodegeneration produces progressive weakness, muscular wasting, and spasticity. The disease starts segmentally before it spreads and causes death from respiratory failure or infection a few years after its onset [3, 4]. However, the modalities and prognosis of disease progression are clinically diverse, including involvement of bulbar muscle and presence of gene mutations [5-7].

Most patients with ALS present with the sporadic form (SALS) of uncertain or degenerative etiology, while approximately 5%–10% of ALS cases are classified as familial (FALS) [5-8]. To date, a number of genetic loci and disease-causing mutations in several genes, including the Cu/Zn superoxide dismutase gene (SOD1),
C9orf72, TARDBP, FUS, OPTN, VCP, UBQLN2, and PFN1, have been reported to be associated with familial and sporadic ALS cases [5-9]. Among these, mutations of SOD1 account for about 15%–20% of all FALS and 2%–4% of all SALS cases, and have revealed a validated genotype-phenotype correlation [8-10]. Herein, we report a p.Gly13Arg mutation in SOD1 exon 1 in a patient with SALS who presented with a rapidly progressive course, predominantly affecting the lower motor neurons.

CASE

A 48-year-old man presented with progressive weakness and muscle atrophy of the left upper and lower limbs, followed by muscle fasciculation and cramping over the course of 5 months. There was no familial history of neuromuscular disease. Both the patient’s parents were still alive without symptoms of muscular weakness or atrophy. Upon evaluation, the Medical Resource Council (MRC) scale revealed 4/5 in the left upper and lower limbs, and prominent muscular atrophy was observed in the left limbs compared to the right limbs. However, other neurological evaluations involving cognition, cranial nerve function, sensory system, speech, and swallowing revealed no abnormality. In addition, the deep tendon reflexes (DTR) of 4-limbs revealed normal or mildly decreased responses, and there were no pathological reflexes such as Babinski and Hoffman’s signs.

Laboratory investigations revealed a normal hemogram, serum electrolytes, liver, thyroid and renal functions with the exception of a mildly elevated serum creatine kinase (CK) level (352 IU/L, normal range; 0-190). The results of tumor screening tests involving alpha-fetoprotein, carcinoembryonic antigen, and cancer antigen (CA)-19-9 were normal. Evaluations for vasculitis involving rheumatoid factor, anti-dsDNA antibody, lupus anticoagulant, antineutrophil cytoplasmic antibody, anti-SSA and SSB (Sjogren syndrome A and B) antibody, anti-Jo-1 antibody and anti-GM1 antibody were within the normal range or negative. Brain magnetic resonance imaging and angiography (MRI and MRA), spinal MRI, Jolly test, and routine nerve conduction study (NCS) were unremarkable.

Electromyography (EMG) of the vastus lateralis, tibialis anterior, peroneus longus, biceps brachii, triceps brachii, first dorsal interosseous, and paraspinal muscles showed large motor unit potentials and denervation potentials of fibrillation and positive sharp waves which were indicative of ALS or other motor neuron diseases [2, 4, 11].

After obtaining informed consent for genetic examination, we tested the SOD1 gene in genomic DNA extracted from peripheral lymphocytes, and a missense mutation of G to C (c.37G>C) in exon 1, and amino acid substitution of arginine for glycine (p.Gly13Arg) was identified by using the sequencing of the SOD1 gene by PCR (Fig. 1).

Clinical findings of our patient were compatible with motor neuron disease (specifically ALS), predominantly affecting the lower motor neurons. The ALS functional rating score (ALSFRS) was 42/48 at 5 months after clinical onset.

Three months after diagnosis, the patient’s symptoms progressed rapidly involving worsening weakness with atrophy, dysarthria and dysphagia. So the patient became wheelchair bound, and ALSFRS was decreased to 32/48 at 3 months after the initial diagnosis of ALS.

DISCUSSION

To date, more than 180 different mutations in the SOD1 gene have been observed in approximately 390 ALS patients (female; 45%, male; 54%), and the mean age of onset was 48 years for patients with a SOD1 mutation (http://alsod.iop.kcl.ac.uk/).

Among these SOD1 mutations, percentage distribution of FALS and SALS was 86% and 13%, respectively, and the proportions of limb and bulbar onset were 89% and 5%, respectively (http://alsod.iop.kcl.ac.uk/).

In this report, we describe an ALS patient with the p.Gly13Arg mutation in SOD1 exon 1, who presented with a sporadic form of the disease and a rapid progressive course over 8 months, with attention to clinical manifestations and genetic evaluation.

A missense mutation of G to C (c.37G>C) in exon 1 and amino acid substitution of arginine for glycine at position 13 (p.Gly13Arg)

![Fig. 1. SOD1 analysis shows a missense mutation of G to C (c.37G>C) in exon 1 and amino acid substitution of arginine for glycine at position 13 (p.Gly13Arg). Arrows indicate a G to C substitution.](image-url)
had been identified in an Italian patient with FALS previously [12, 13].

To our knowledge, our patient is the second ALS case with the p.Gly13Arg mutation since that report; furthermore, this is the first report identifying this mutation in the Korean population [8, 9]. Interestingly, the clinical implications of this case revealed a different phenotype of the sporadic form of ALS and clinical course, including onset age and rapid progression as compared with the Italian case [12-14].

In the Italian case, a male patient developed weakness of the left lower limb at age 63. At age 67, neurological examination showed mild weakness and wasting of the distal muscles in the lower limbs with muscle fasciculation. The ankle jerks were absent and plantar responses were normal with no signs of bulbar involvement. A similarly slow progression was reported in the patient’s father, who also presented with primary involvement of the lower limb muscles, followed by bulbar symptoms found at 4 years after disease onset [12, 13].

Our patient showed predominantly lower motor neuron signs without apparent upper motor neuron signs which indicate the similarities with the Italian case. Therefore, this clinical feature indicates a possible clinic-genetic phenotype of ALS patients with a p.Gly13Arg mutation of SOD1. However, our patient showed a younger onset age (age 48 versus age 62), and had no apparent familial history of ALS. The patient’s parents were still alive without motor neuron signs. In addition to the different age of onset and familial history, our patient presented a differentiated clinical feature that was rapid progressive course with predominant involvement of lower motor neurons, while the Italian patient had a slower progressive course with predominantly lower motor neuron signs.

In conclusion, this case of p.Gly13Arg SOD1 mutation in SALS differs clinically from previous report of FALS, and expands the variations of ALS phenotypes associated with SOD1 gene mutations. To our knowledge, this is the first report identifying the p.Gly13Arg mutation of SOD1 in the Korean population. Further clinical assessments on the patient’s disease course and genetic analysis of related subjects will be necessary to validate the clinical characteristics of ALS with a p.Gly13Arg SOD1 mutation in the Korean population.

ACKNOWLEDGEMENTS

This research was supported by the Chung-Ang University Graduate Research Scholarship (2016), and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2016R1D1A1B03936287).

REFERENCES


